Cancer's Growth Protein MYC Found to Secretly Repair Chemo-Damaged DNA
MYC protein doesn't just fuel tumor growth — it also repairs DNA damage from chemotherapy, revealing a key resistance mechanism.
Summary
Scientists at Oregon Health & Science University have discovered that MYC, a protein overactive in most human cancers, has a hidden role beyond driving tumor growth. It also rushes to sites of DNA damage and recruits repair proteins, helping cancer cells survive chemotherapy and radiation. This dual function may explain why some aggressive cancers — especially pancreatic cancer — resist treatment so effectively. The findings, published in Genes & Development, suggest that blocking MYC's DNA repair activity could make these hard-to-treat cancers significantly more vulnerable to existing therapies. Researchers are now investigating whether targeting this mechanism could improve outcomes for patients with cancers where MYC is highly active.
Detailed Summary
Cancer treatment resistance is one of the biggest obstacles in oncology, and new research from Oregon Health & Science University may have uncovered a major reason why some tumors survive therapies designed to destroy them. The culprit is MYC, a protein already notorious for driving uncontrolled tumor growth that turns out to have a second, previously underappreciated role in keeping cancer cells alive.
The study, published in Genes & Development, found that a modified form of MYC physically relocates to sites of DNA damage within cancer cells. Once there, it acts as a recruiter, gathering the repair proteins needed to fix dangerous DNA breaks. This is a non-canonical function — meaning it operates outside MYC's well-known role of switching growth genes on — and it appears to be particularly active when cells are under treatment stress.
This discovery is especially significant for pancreatic cancer, one of the deadliest cancers known, where MYC activity is abnormally high. Chemotherapy and radiation work by inflicting DNA damage too severe for cells to survive. If MYC is efficiently repairing that damage, it effectively neutralizes the treatment before it can finish the job, allowing tumors to recover and continue growing.
The practical implication is promising: if researchers can develop therapies that block MYC's DNA repair function specifically, existing chemotherapy regimens could become far more lethal to tumor cells. This would not require inventing entirely new treatments — it could amplify what already exists.
Caveats remain. This research is preclinical, meaning it has not yet been tested in human clinical trials. The mechanisms observed in lab settings do not always translate directly to patient outcomes. Further work is needed to develop safe and targeted MYC inhibitors that disrupt repair without harming healthy cells, and to confirm these findings across diverse cancer types.
Key Findings
- MYC protein directly travels to DNA damage sites and recruits repair machinery in tumor cells.
- This DNA repair role helps cancer cells survive chemotherapy and radiation that would otherwise kill them.
- Pancreatic cancer, where MYC is highly overactive, may be especially vulnerable to blocking this mechanism.
- Targeting MYC's repair function could enhance effectiveness of existing chemotherapy without new drug classes.
- Findings published in peer-reviewed journal Genes & Development from a credible research institution.
Methodology
This is a research news summary based on a peer-reviewed study published in Genes & Development by researchers at Oregon Health & Science University. The source institution is a credible academic medical center. The evidence basis is experimental laboratory research; specific model systems (cell lines, animal models) are not detailed in the summary article.
Study Limitations
This research is preclinical and has not yet been validated in human clinical trials, limiting immediate clinical application. The article does not specify which experimental models were used, making it difficult to assess translational readiness. Readers should consult the primary Genes & Development paper for full methodology, effect sizes, and model details.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.